Merck Announces U.S. FDA Grants Tentative Approval for Lusduna Nexvue (insulin glargine injection), a Follow-On Biologic Basal Insulin
KENILWORTH, N.J.--(BUSINESS WIRE) July 20, 2017 --Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for Lusduna Nexvue (insulin...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Canada Health | Drugs & Pharmacology | Food and Drug Administration (FDA) | Grants | Insulin | Lantus | Merck | New Drug Applications | USA Health